Clinical Trials Sponsored by Mundipharma CVA

Total 4863 results

Mundipharma Research GmbH & Co KG

Completed

Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain (HMX3501)

Constipation

Romania, Switzerland, Israel, Belgium, Germany, Australia, Austria, Czech Republic, Denmark, Finland, France, Netherlands, Poland, United Kingdom
IRCCS San Raffaele
Mundipharma K.K.

Unknown

High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement (SCNSL1)

B-Cell Lymphomas

Italy
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 40 mg Fasted-state Bioequivalence Study

Chronic Pain

China
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study

Pain

China
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain

Cancer Pain

China
Mundipharma Research GmbH & Co KG

Completed

Oxycodone-naloxone in Relieving Opioid-related Constipation

Pain
Mundipharma Research GmbH & Co KG

Completed

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

Pain | Cancer | Constipation

United Kingdom
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Immediate-Release Oxycodone Capsules Study in Cancer Pain

Cancer
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment

Other Acute Postoperative Pain

China
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Norspan Transdermal Patches Study in Osteoarthritis Patients

Osteoarthritis Disorders

China
Mundipharma Research GmbH & Co KG

Completed

A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

Parkinson's Disease With Severe Pain

United Kingdom, Spain, Germany, Hungary, Czech Republic, Poland, Romania
Mundipharma Research GmbH & Co KG

Completed

A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy

Moderate to Severe Pain Due to Diabetic Polyneuropathy

Germany
Norpharma A/S
Mundipharma Finland

Completed

Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine

Pain | Osteoarthritis

Finland
Mundipharma Pharmaceuticals srl
Bioikos Ambiente Srl

Completed

Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX®): Efficacy and Safety Study (MEDITA) (MEDITA)

Acute Traumatic Pain

Italy
CellAct Pharma GmbH
Mundipharma-EDO GmbH

Terminated

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors (CAP7-1)

Advanced Endstage Solid Carcinomas in Adults

Germany
University Hospital, Grenoble
Mundipharma Pte Ltd.

Completed

Multimodal Oral Analgesia for Trauma in the Emergency Department (START)

Pain

France
King's College London
Mundipharma Research Limited

Recruiting

European Cohort Study of the Effectiveness of Take Home Naloxone (NalPORS)

Opioid Overdose

Denmark, United Kingdom, Sweden
Arbeitsgemeinschaft medikamentoese Tumortherapie
Mundipharma Pte Ltd.

Completed

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
Light Sciences Oncology
Mundipharma Research Limited

Completed

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Qualitouch-HC Foundation
Mundipharma Pte Ltd.

Completed

Quality Assurance of Electronic Data Capturing (EDC) in Pain Treatment

Pain

Switzerland
AstraZeneca
Hutchison MediPharma

Recruiting

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Carcinoma

Denmark, Spain, United States, Taiwan, Vietnam, Canada, Korea, Republic of, Brazil, India, Japan, Italy, Puerto Rico, France, Chile
University Hospital Inselspital, Berne
Mundipharma Medical Company

Completed

Bendamustine and Melphalan in Myeloma (BEB-2)

Multiple Myeloma

Switzerland
Azienda Ospedaliera di Bolzano
Mundipharma Pte Ltd.

Completed

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Multiple Myeloma

Italy
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.

Completed

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

T-cell Lymphoma

France
Nordic Lymphoma Group
Mundipharma Pte Ltd.; Amgen

Completed

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis (CHIC)

Primary Disease

Denmark, Finland, Norway, Sweden
National University Hospital, Singapore
Mundipharma Pte Ltd.

Unknown

The Efficacy and Safety of 3% Povidone-Iodine in Acne Therapy

Acne

Singapore
Cantonal Hospital of St. Gallen
Celgene Corporation; Amgen; Mundipharma Medical Company; Mundipharma Research GmbH...

Completed

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

Multiple Myeloma

Switzerland
Biofourmis Singapore Pte Ltd.
Mundipharma Research Limited

Completed

Continuous Monitoring of Physiology and Self-reported Pain Score Amongst Post-surgical Knee Patients (ObservePAIN)

Knee Arthroplasty

Singapore
Mundipharma Manufacturing Pte Ltd.
Singapore Polytechnic (SP)

Completed

The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome

Oral Health

Singapore
Hutchison Medipharma Limited

Recruiting

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma With EZH2

China
Hutchison Medipharma Limited

Recruiting

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin's Lymphoma

China
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

China
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine
Hutchison Medipharma Limited

Active, not recruiting

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

Metastatic Colorectal Cancer | Metastatic Colon Cancer

United States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
Hutchison Medipharma Limited

Completed

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Healthy Subject

China
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Hutchison Medipharma Limited

Active, not recruiting

Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP)

China
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Hutchison Medipharma Limited

Completed

Surufatinib DDI With a PPI and a CYP3A Inducer

Healthy

United States
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Healthy

United States
Hutchison Medipharma Limited

Unknown

HMPL-813 in Treating Patients With Glioblastoma

Glioblastoma

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Healthy

China
Hutchison Medipharma Limited

Completed

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Solid Tumor

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Hutchison Medipharma Limited

Unknown

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor, Adult

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China

Clinical Trials Sponsored by Mundipharma CVA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations